At the news
? BULLISHIMPACT 7/10 8-K filed Apr 27, 2026 at 16:17 ET
Erasca announced positive preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing robust monotherapy response rates in KRAS G12X NSCLC (62% uORR8wk at PADs) and PDAC (40% uORR14wk) that exceeded comparator RMC-6236 by 24 and 11 percentage points, respectively. The data also demonstrated favorable safety with no DLTs and durable responses, supporting advancement into expansion cohorts ahead of schedule.
- ERAS-0015 achieved 62% uORR8wk at PADs in 2L+ KRAS G12X NSCLC (N=37), exceeding comparator RMC-6236 by 24 percentage points.
- In PDAC, 40% uORR14wk at PADs (N=20) exceeded comparator by 11 percentage points.
- No DLTs observed; mostly low-grade AEs with no discontinuations due to TRAEs.
- Monotherapy RDEs set at 24 mg and 32 mg QD; combination dose escalation with panitumumab initiated.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access